116 related articles for article (PubMed ID: 15159503)
1. Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan.
Fischer L; Thiel E; Klasen HA; Kirchen H; Jahnke K; Korfel A
Neurology; 2004 May; 62(10):1885-7. PubMed ID: 15159503
[TBL] [Abstract][Full Text] [Related]
2. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
Voloschin AD; Betensky R; Wen PY; Hochberg F; Batchelor T
J Neurooncol; 2008 Jan; 86(2):211-5. PubMed ID: 17896078
[TBL] [Abstract][Full Text] [Related]
3. Prospective trial on topotecan salvage therapy in primary CNS lymphoma.
Fischer L; Thiel E; Klasen HA; Birkmann J; Jahnke K; Martus P; Korfel A
Ann Oncol; 2006 Jul; 17(7):1141-5. PubMed ID: 16603598
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
5. Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906.
Smith SM; Johnson JL; Niedzwiecki D; Eder JP; Canellos G; Cheson BD; Bartlett NL;
Leuk Lymphoma; 2006 Aug; 47(8):1511-7. PubMed ID: 16966261
[TBL] [Abstract][Full Text] [Related]
6. Primary central nervous system lymphoma (PCNSL) in immunocompetent adults: analysis of a retrospective series of patients treated using idarubicin-containing regimen and radiotherapy.
Vigliotti ML; Dell'Olio M; La Sala A; Romano G; Tartarone A; Mele G; Musto C; Carella AM; Di Renzo N
Hematol J; 2004; 5(5):453-5. PubMed ID: 15448676
[No Abstract] [Full Text] [Related]
7. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy?
O'Neill BP; O'Fallon JR; Earle JD; Colgan JP; Brown LD; Krigel RL
Int J Radiat Oncol Biol Phys; 1995 Oct; 33(3):663-73. PubMed ID: 7558957
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
9. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Cabanillas F
Semin Hematol; 1999 Oct; 36(4 Suppl 8):11-5. PubMed ID: 10622224
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.
Kraut EH; Balcerzak SP; Young D; Davis MP; Jacobs SA;
Cancer Invest; 2002; 20(2):174-9. PubMed ID: 11901536
[TBL] [Abstract][Full Text] [Related]
13. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network.
Langner-Lemercier S; Houillier C; Soussain C; Ghesquières H; Chinot O; Taillandier L; Soubeyran P; Lamy T; Morschhauser F; Benouaich-Amiel A; Ahle G; Moles-Moreau MP; Moluçon-Chabrot C; Bourquard P; Damaj G; Jardin F; Larrieu D; Gyan E; Gressin R; Jaccard A; Choquet S; Brion A; Casasnovas O; Colin P; Reman O; Tempescul A; Marolleau JP; Fabbro M; Naudet F; Hoang-Xuan K; Houot R
Neuro Oncol; 2016 Sep; 18(9):1297-303. PubMed ID: 26951382
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
[TBL] [Abstract][Full Text] [Related]
15. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
[TBL] [Abstract][Full Text] [Related]
16. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
[TBL] [Abstract][Full Text] [Related]
17. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.
Nitschke R; Parkhurst J; Sullivan J; Harris MB; Bernstein M; Pratt C
J Pediatr Hematol Oncol; 1998; 20(4):315-8. PubMed ID: 9703003
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial.
Zeremski V; Koehler M; Fischer T; Schalk E
Ann Hematol; 2016 Apr; 95(5):793-9. PubMed ID: 26801791
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
